Servicios Personalizados
Revista
Articulo
Indicadores
- Citado por SciELO
- Accesos
Links relacionados
- Similares en SciELO
Compartir
Gaceta médica de México
versión On-line ISSN 2696-1288versión impresa ISSN 0016-3813
Resumen
IGNACIO-IBARRA, Gregorio et al. A proposal for the management of COVID-19-induced coagulopathy in adults. Gac. Méd. Méx [online]. 2021, vol.157, n.2, pp.209-214. Epub 23-Jun-2021. ISSN 2696-1288. https://doi.org/10.24875/gmm.20000930.
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is the cause of the coronavirus disease 2019 (COVID-19) pandemic, which has a high case fatality rate. Most severely ill patients develop a special type of coagulopathy that had not been described before and that is now considered the main cause of death. For this reason, anticoagulant treatment has become one of the cornerstones of the treatment of this infection. However, the rate at which the evidence regarding the use of anticoagulants is generated is quite fast, and sometimes it is difficult to interpret and conflicting. After having performed an extensive review of the published literature, this proposal for the use of anticoagulant treatment is made, taking into account available resources in Mexico.
Palabras llave : COVID-19; Coagulopathy Disseminated intravascular coagulation; Anticoagulants Venous thromboembolic disease.